Amneal Pharmaceuticals Stock News

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) CEO Chirag K. Patel bought 100,000 shares of the companys stock in a transaction that occurred on Wednesday, December 15th. The shares were bought at an average price of $4.13 per share, for a total transaction of $413,000.00. The transaction was disclosed in a legal filing with the SEC, which can []

Insiders are buying these penny stocks during "tax loss season" The post Penny Stocks To Buy Now According To Insiders In December 2021 appeared first on Penny Stocks to Buy, Picks, News and Informati

The Hydroxychloroquine Market report focus on the current trends of the market along with detailed analysis which provides data regarding this market rate, and it also predicts the future market growth rate. The Hydroxychloroquine Market study includes research on the

The global Shoulder Pain Treatment market size is projected to reach US$ 3.6 Billion by 2027, at a CAGR of 8.1% during 2021-2027. Globally, the geriatric population is growing at an unprecedented rate. Shoulder pain is a frequent and debilitating

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of New York LLC (collectively Amneal). As part of the settlement, TherapeuticsMD granted to Amneal a license to commercialize Amneals generic version of BIJUVA (1 mg estradiol and 100 mg p

TherapeuticsMD Inc (NASDAQ: TXMD) has settled the previously disclosed U.S. patent litigation for Bijuva with Amneal Pharmaceuticals Inc (NYSE: AMRX). Bijuva is a prescription medicine used to tr

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) has received an average recommendation of Buy from the seven research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target []

Shares of Amneal Pharmaceuticals, Inc. have earned a consensus rating of Buy from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One

Shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) have earned a consensus rating of Buy from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The [] The post Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Given Average Rating of Buy by Brokerages appeared first on ETF Daily News .

California State Teachers Retirement System lessened its stake in Amneal Pharmaceuticals, Inc. (NYSE:AMRX) by 8.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 137,352 shares of the companys stock after selling 12,187 shares during the quarter. California State Teachers Retirement Systems holdings in Amneal []

Man Group plc purchased a new position in shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) in the second quarter, HoldingsChannel reports. The fund purchased 13,158 shares of the companys stock, valued at approximately $67,000. Several other hedge funds and other institutional investors have also recently modified their holdings of AMRX. Dimensional Fund Advisors LP grew its []

LPL Financial LLC grew its stake in Amneal Pharmaceuticals, Inc. (NYSE:AMRX) by 7.9% in the 2nd quarter, Holdings Channel.com reports. The fund owned 32,622 shares of the companys stock after purchasing an additional 2,383 shares during the quarter. LPL Financial LLCs holdings in Amneal Pharmaceuticals were worth $167,000 as of its most recent SEC filing. []

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for difluprednate ophthalmic emulsion 0.05%, which is the generic version of Durezol® and is used in the treatment of inflammation and pain associated with ocular surgery. “With the approval of difluprednate, a complex ophthalmic suspension product, we conti

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2021 Results - Earnings Call Transcript

Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q3 revenue of $529 million, a marginal increase of 2% Y/Y, missing the consensus of $545.06 million. The increase was driven by Generic product launche